Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
So it remains unclear if GLP-1s reduce clotting risk because folks lose weight or whether some other mechanism is at play
The decision to adjust dose based on heart rate should involve the overall clinical picture, not just one number in isolation
There is hope that new drugs and a better understanding of obesity will help reduce stigma and fat-shaming, just as awareness of mental health helped break the taboo around antidepressants
Your body begins adapting to GLP-1, GIP, and glucagon receptor activation simultaneously
One possible explanation is that the anti-inflammatory and neuroimmune effects of GLP-1 receptor activation may occur at lower levels of receptor engagement than the metabolic effects (like weight loss or appetite suppression)
In addition, patients with major depressive disorder may suffer from either increases or decreases in appetite and weight during a depressive episode (Milaneschi et al., 2019), which is associated with differences in energy metabolism (Simmons et al., 2018) and function of the reward circuit (Kroemer et al., 2022
